[Treatment of allergic rhinitis with asthma by different ways of inhaling corticosteroids].
OBJECTIVE
To observe the therapeutical effect on allergic rhinitis with asthma by different ways of inhaling corticosteroids.


METHODS
Ninety patients suffering from allergic rhinitis with asthma were classified into three groups in random and treated with budesonide (BUD) by nasal spray, inhaling and nasal spray-inhaling combined administration for 12 weeks, respectively. The concentration of serum total IgE, eosinophil cationic protein (ECP) and IL-5, pulmonary functions were examined before and after treatment.


RESULTS
The improvement of symptom scores of rhinitis and asthma in three groups were significant (P < 0.05). The concentration of serum total IgE, ECP and IL-5 in three groups decreased greatly after treatment (P < 0.05). There were significant improvement in FEV1, FEV1/FVC and FEF25%-75% in inhaling group before and after treatment (P < 0.05): FEV1 from (2.04 +/- 0.45) L to (2.47 +/- 0.54) L, FEV1/FVC from (72.73 +/- 5.59)% to (75.42 +/- 5.94)% and FEF25%-75% from 1.69 +/- 0.52 to 2.06 +/- 0.77. There was also significant improvement in nasal spray-inhaling combined groups before and after treatment (P < 0.05): FEV1 from (2.32 +/- 0.56) L to (2.76 +/- 0.58) L, FEV1/FVC from (73.80 +/- 4.17)% to (76.04 +/- 4.49)% and FEF25%-75% from 2.09 +/- 0.45 to 2.34 +/- 0.64. The significant difference of FEV1 among the three treatment groups was observed (P = 0.041).


CONCLUSIONS
The symptoms of rhinitis and asthma in three groups by three ways of inhaling BUD were greatly improved, no significant difference in symptom scores and serum parameters was found.
Zhang
Hua
H
Department of Otorhinolaryngology, First Affiliated Hospital, Xinjiang Medical University, Urumqi, 830054, China. hzhang1106@yahoo.com.cn
Chen
Xuan
X
Wang
Hui-wu
HW
Xiang
Yang-bing
YB
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use*; D000328:Adult; D001249:Asthma / Q000150:complications / Q000188:drug therapy*; D019819:Budesonide / Q000627:therapeutic use*; D047150:Eosinophil Cationic Protein / Q000097:blood; D005260:Female; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood; D015848:Interleukin-5 / Q000097:blood; D008297:Male; D008875:Middle Aged; D012221:Rhinitis, Allergic, Perennial / Q000150:complications / Q000188:drug therapy*; D016896:Treatment Outcome; D055815:Young Adult
D000305:Adrenal Cortex Hormones; C508599:IL5 protein, human; D015848:Interleukin-5; D007073:Immunoglobulin E; D019819:Budesonide; D047150:Eosinophil Cationic Protein